Log in  First Connection?

VirusArchives

Penile HPV prevalence among high-risk men in Sri Lanka: baseline insight for HPV prevention strategies in a lower-middle-income country
Virus
 1 min.

 Published on 18/06/2026 |  Original article (Full-text)  | Amarasena, W. D. J. K. et al. | Infectious Agents and Cancer. Volume 21(1).

Human Papillomavirus (HPV) infection is the most common sexually transmitted viral infection in the world. Persistent infection lasting more than two years, particularly with High-Risk (HR) HPV genotypes, can lead to malignant transformation. Estimating HPV prevalence among high-risk men in Sri Lanka...

Five years of SARS-CoV-2 evolution: variants, mechanisms, and public health challenges
Virus
 1 min.

 Published on 11/06/2026 |  Original article (Full-text)  | Gonzalo Emiliano Aranda-Abreu et al. | Future Virology 2026; 21(5): 351-363

Since its emergence in 2019, SARS-CoV-2 has shown remarkable evolutionary plasticity, profoundly shaping the course of the COVID-19 pandemic. This review summarizes key evolutionary milestones from 2019 to 2025, highlighting mechanisms such as point mutations, positive selection, recombination, and evolution...

Is dose adjustment of dolutegravir necessary in Chinese adults living with HIV across different body weight levels? A population pharmacokinetics analysis
Virus
 1 min.

 Published on 04/06/2026 |  Original article (Full-text)  | Rui Chen et al. | Expert Review of Clinical Pharmacology 2026; aop:10.1080/17512433.2026.2679589

Dolutegravir (DTG) is an integrase strand transfer inhibitor indicated for human immunodeficiency virus (HIV) infection. Although intrinsic factors show no ethnic-specific impact on DTG pharmacokinetics, extrinsic factors may modulate its pharmacokinetic profile. This study developed a population pharmacokinetic...

Decline of HIV infection: legacy of tenofovir (A. Holý) and rilpivirine (P. Janssen)
Virus
 1 min.

 Published on 28/05/2026 |  Original article (Full-text)  | Erik De Clercq et al. | Future Virology 2026; 21(5): 365-372

Among the wide variety of antivirals that have been developed for the treatment of human immunodeficiency virus (HIV) infections and acquired immunodeficiency syndrome (AIDS), two stand out: tenofovir and rilpivirine. The names unmistakenly associated with the discovery of these two compounds, are Antonín...